Continuous immunosuppressive treatment after solid organ transplantation is associated with an increased incidence of therapy-related AML (t-AML). 1 The prognosis of t-AML is poor and the treatment with the highest potential for cure is allogeneic hematopoietic cell transplantation (Allo-HCT). 2, 3 We report the first case of Allo-HCT for t-AML that developed after liver transplantation (LTX) from the identical donor.
A 66-year-old male patient with hepatitis C-induced liver cirrhosis received LTX from his HLA haploidentical son followed by continuous immunosuppression with CsA 75 mg/day. Three years later, t-AML was diagnosed (45,X,-Y, t(8;21)(q22;q22)) and induction therapy according to the MICE protocol (mitoxantron 7 mg/m 2 on days 1, 3 and 5, etoposide 100 mg/m 2 on days 1-3 and cytarabin 100 mg/m 2 on days 1-7) was given. AML persisted after the first cycle and short-term aplasia after the second cycle of MICE was followed by increasing blast counts. To induce aplasia prior Allo-HCT, sequential high dose AraC and mitoxantrone (S-HAM) chemotherapy (AraC 2 Â 1 g/m 2 /day for 4 days; mitoxantron 10 mg/m 2 for 2 days) was given. Allo-HCT from the same haploidentical son was performed with a CD34 þ -selected graft (14.5 Â 10 6 CD34 þ /kg body weight) after conditioning (melphalan 140 mg/m 2 /day on day -8, fludarabin 30 mg/m 2 /day on days À8 to À4, thiotepa 5 mg/kg/day on days À7 to À4, antithymocyte globulin Fresenius (ATG-F) 5 mg/kg/day for 5 days). Acute skin GvHD grade 2 developed on day þ 23, which responded to CsA and prednisolone. No evidence for liver failure was found ( Figure 1a ). Post-Allo-HCT CR and sustained 100% donor chimerism were achieved. One year after Allo-HCT, the patient developed Pneumocystis Jirovecii pneumonia and passed away with no evidence for residual AML cells. T-cell counts were severely reduced in the post-Allo-HCT course, which made the patient susceptible to infections (Figure 1b) . Several potential factors explain the poor outcome of patients with t-AML. Depletion of hematopoietic stem cells because of previous immunosuppressive therapy in t-AML causes prolonged cytopenias after chemotherapy. Our case, however, tolerated chemotherapy well despite impaired liver function. Furthermore, patients with t-AML that have been chronically immunosuppressed may have dysfunctional T cells and B cells leading to colonization with opportunistic pathogens. 4 Also unfavorable cytogenetics may contribute to the increased resistance in t-AML. The karyotype of our patient suggests the acquisition of multiple chromosomal aberrations. As t-AML develops in the milieu of chemotherapy, the malignant clone is likely relatively drugresistant. This hypothesis is supported by the reported frequent expression of the multidrug-resistance phenotype 4 and low remission rates in t-AML. 5 This is compatible with our patient who failed to achieve CR with induction chemotherapy. 6 Currently, published reports include cases of sibling Allo-HCT after unrelated cadaveric LTX for aplastic anemia, 7 matched unrelated Allo-HCT after cadaveric LTX in a patient with hyperimmunoglobulin M syndrome, 8 combined transplantation of BM and liver from a cadaveric donor for liver cancer 9 and Allo-HCT after orthotopic LTX for hemophagocytic lymphohistiocytosis. 10 These 
